Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > G12C/G12V KRAS mutation in PC & CRC patients respond to Pela

<< Previous

Bullboard Posts

Next >>

Comment by JohnnyYegon Oct 06, 2023 11:37am

150 Views

Post# 35673228

RE:RE:RE:RE:RE:RE:G12C/G12V KRAS mutation in PC & CRC patients respond to Pela

Foxy - remember that PanCAN signed us on for a reason, and THEN gave us another cash injection for an additional arm. THEY have done their due diligience and if there were any indications that Matt or mgmt were pissing around, they would have passed us by.

On this road with ONCY, patience is truly a virtue (you've read some of my rants recently lol) but as hard as it is for me perosnlly right now, I am giving them until the ESMO timeline (+/- a few days). After that who knows?? (Right, I'll keep holding and b*tching....haha)

<< Previous

Bullboard Posts

Next >>

Standard Lithium wins up to $225M provisional grant from U.S. DOE